New CEO Linus Bosaeus brings a commercial focus

December 12, 2021

”We plan to have a fully certified product on the market by 2023, but the method is already being tested in healthcare for use as soon as possible”, says Linus Bosaeus, new CEO of Rarity Bioscience AB in interview on Uppsala University Invest.

Read the full article at https://uuinvest.se/precisionsdiagnstik-i-fokus-for-rarity-bioscience/
(Article in Swedish)

Share this article

Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultra-Sensitive superRCA Assay

UPPSALA, SWEDEN, and SALT LAKE CITY (February 3, 2026) –

Rarity Bioscience Expands into the United States

With a growing customer base in North America, Rarity Bioscience

Rarity Bioscience wins prestigious Disruptive Technology Award

Rarity Bioscience has received the prestigious Disruptive Technology Award for

New CEO Linus Bosaeus brings a commercial focus

Rarity Bioscience Announces That ARUP Laboratories Has Become the First U.S. Reference Lab To Validate Its Ultra-Sensitive superRCA Assay

Rarity Bioscience Expands into the United States

Rarity Bioscience wins prestigious Disruptive Technology Award

Deep dive into the technology and learn how to access the innovation

Company

Explore

Gain access to our content!